Agios collapsed ~50% in a single day after its pivotal RISE UP sickle cell disease, SCD trial delivered a split verdict: it met the hemoglobin (Hb) response endpoint but failed to show a statistically ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results